International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH); Guidance for Industry on “Target Animal Safety for Veterinary Pharmaceutical Products,” VICH GL43; Availability, 19096-19097 [E9-9521]
Download as PDF
19096
Federal Register / Vol. 74, No. 79 / Monday, April 27, 2009 / Notices
FOR FURTHER INFORMATION CONTACT:
Maribeth Badura, Director, Division of
Healthy Start and Perinatal Services,
Maternal and Child Health Bureau,
HRSA, Room 18–12, Parklawn Building,
5600 Fishers Lane, Rockville, Maryland
20857; telephone (301) 443–0543;
e-mail MBadura@hrsa.gov.
Management (HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic comments to https://
www.regulations.gov. See the
SUPPLEMENTARY INFORMATION section for
electronic access to the guidance
document.
Dated: April 21, 2009.
Marcia K. Brand,
Deputy Administrator.
[FR Doc. E9–9517 Filed 4–24–09; 8:45 am]
FOR FURTHER INFORMATION CONTACT:
Steven Vaughn, Center for Veterinary
Medicine, (HFV–100), Food and Drug
Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240–276–8300, email: steven.vaughn@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2007–D–0430] (formerly
Docket No. 2007D–0166)
International Cooperation on
Harmonisation of Technical
Requirements for Registration of
Veterinary Medicinal Products (VICH);
Guidance for Industry on ‘‘Target
Animal Safety for Veterinary
Pharmaceutical Products,’’ VICH GL43;
Availability
AGENCY:
Food and Drug Administration,
HHS.
pwalker on PROD1PC71 with NOTICES
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a guidance for industry
(#185) entitled ‘‘Target Animal Safety
for Veterinary Pharmaceutical
Products,’’ VICH GL43. The purpose of
this harmonized guidance is to provide
recommendations regarding target
animal safety (TAS) evaluation for
regulatory submission of an
Investigational Veterinary
Pharmaceutical Product (IVPP), which
is appropriate for determining the safety
of an IVPP in the target animal. The
guidance includes recommendations on
including identification of target organs,
where possible, and confirmation of
margin of safety, using the minimum
number of animals appropriate for the
studies.
DATES: Submit written or electronic
comments on agency guidances at any
time.
ADDRESSES: Submit written requests for
single copies of the guidance to the
Communications Staff (HFV–12), Center
for Veterinary Medicine, Food and Drug
Administration, 7519 Standish Pl.,
Rockville, MD 20855. Send one selfaddressed adhesive label to assist that
office in processing your requests.
Submit written comments on the
guidance to the Division of Dockets
VerDate Nov<24>2008
15:55 Apr 24, 2009
Jkt 217001
I. Background
In recent years, many important
initiatives have been undertaken by
regulatory authorities and industry
associations to promote the
international harmonization of
regulatory requirements. FDA has
participated in efforts to enhance
harmonization and has expressed its
commitment to seek scientifically based
harmonized technical procedures for the
development of pharmaceutical
products. One of the goals of
harmonization is to identify and then
reduce differences in technical
requirements for drug development
among regulatory agencies in different
countries.
FDA has actively participated in the
International Conference on
Harmonisation of Technical
Requirements for Approval of
Pharmaceuticals for Human Use (VICH)
for several years to develop harmonized
technical requirements for the approval
of human pharmaceutical and biological
products among the European Union,
Japan, and the United States. The VICH
is a parallel initiative for veterinary
medicinal products. The VICH is
concerned with developing harmonized
technical requirements for the approval
of veterinary medicinal products in the
European Union, Japan, and the United
States, and includes input from both
regulatory and industry representatives.
The VICH Steering Committee is
composed of member representatives
from the European Commission,
European Medicines Evaluation Agency,
European Federation of Animal Health,
Committee on Veterinary Medicinal
Products, the U.S. FDA, the U.S.
Department of Agriculture, the Animal
Health Institute, the Japanese Veterinary
Pharmaceutical Association, the
Japanese Association of Veterinary
Biologics, and the Japanese Ministry of
Agriculture, Forestry and Fisheries.
Four observers are eligible to
participate in the VICH Steering
Committee: One representative from the
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
government of Australia/New Zealand,
one representative from the industry in
Australia/New Zealand, one
representative from the government of
Canada, and one representative from the
industry of Canada. The VICH
Secretariat, which coordinates the
preparation of documentation, is
provided by the International
Federation for Animal Health (IFAH).
An IFAH representative also
participates in the VICH Steering
Committee meetings.
II. Guidance on Target Animal Safety
for Veterinary Pharmaceutical Products
In the Federal Register of May 18,
2007 (72 FR 28058), FDA published the
notice of availability for a draft guidance
entitled ‘‘Draft Guidance for Industry on
Target Animal Safety for Veterinary
Pharmaceutical Products,’’ which gave
interested persons until June 18, 2007,
to comment on the draft guidance. FDA
received a few comments on the draft
guidance and those comments as well as
those received by other VICH member
regulatory agencies were considered as
the guidance was finalized. Based on
the comments received, the VICH Expert
Working Group on Target Animal Safety
clarified the guidance’s
recommendations regarding the
development and conduct of TAS
studies. In particular, the Expert
Working Group revised the sections
addressing necropsy and histopathology
examinations and mammary gland
studies to clarify the recommendations
regarding these topics. At a meeting
held in July 2008, the VICH Steering
Committee endorsed the final guidance
for industry, (VICH GL43). The guidance
announced in this notice finalizes the
draft guidance dated May 18, 2007.
This guidance document is intended
to cover TAS evaluation for any IVPP
used in the following species: Bovine,
ovine, caprine, feline, canine, porcine,
equine, and poultry (chickens and
turkeys). The recommendations in this
guidance may not be appropriate for
registration by national or regional
authorities of products for use in minor
species or minor uses. The guidance
does not provide information for the
design of TAS studies in other species,
including aquatic animals. For other
species and for minor uses, TAS studies
should be designed following national
or regional guidance.
III. Significance of Guidance
This guidance document, developed
under the VICH process, has been
revised to conform to FDA’s good
guidance practices regulation (21 CFR
10.115). For example, the document has
been designated ‘‘guidance’’ rather than
E:\FR\FM\27APN1.SGM
27APN1
Federal Register / Vol. 74, No. 79 / Monday, April 27, 2009 / Notices
‘‘guideline.’’ In addition, guidance
documents must not include mandatory
language such as ‘‘shall,’’ ‘‘must,’’
‘‘require,’’ or ‘‘requirement,’’ unless
FDA is using these words to describe a
statutory or regulatory requirement. The
guidance represents agency’s current
thinking on the topic. It does not create
or confer any rights for or on any person
and does not operate to bind FDA or the
public. An alternative approach may be
used if such approach satisfies the
requirements of applicable statutes and
regulations.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously
approved collections of information
found in FDA regulations. These
collections of information are subject to
review by the Office of Management and
Budget (OMB) under the Paperwork
Reduction Act of 1995 (44 U.S.C. 3501–
3520). The collections of information in
sections 1–5 of the guidance have been
approved under OMB control no. 0910–
0032 (expiration date April 30, 2010).
V. Comments
Interested persons may submit to the
Division of Dockets Management (see
ADDRESSES) written or electronic
comments regarding this document.
Submit a single copy of electronic
comments or two paper copies of any
mailed comments, except that
individuals may submit one paper copy.
Comments are to be identified with the
docket number found in brackets in the
heading of this document. Received
comments may be seen in the Division
of Dockets Management between 9 a.m.
and 4 p.m., Monday through Friday.
VI. Electronic Access
Persons with access to the Internet
may obtain the guidance at either https://
www.fda.gov/cvm or https://
www.regulations.gov.
Dated: April 20, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–9521 Filed 4–24–09; 8:45 am]
BILLING CODE 4160–01–S
Times and Dates:
8 a.m.–8:15 a.m., April 27, 2009 (Open).
8:15 a.m.–4 p.m., April 27, 2009 (Closed).
Place: Teleconference, Toll Free Number:
(877) 468–4185, Participant Pass code: 447–
5689.
Status: Portions of the meetings will be
closed to the public in accordance with
provisions set forth in Section 552b(c)(4) and
(6), Title 5, U.S.C., and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Section
10(d) of Public Law 92–463.
Purpose: This group is charged with
providing advice and guidance to the
Secretary, Department of Health and Human
Services, and the Director, CDC, concerning
the scientific and technical merit of grant and
cooperative agreement applications received
from academic institutions and other public
and private profit and nonprofit
organizations, including State and local
government agencies, to conduct specific
injury research that focuses on prevention
and control.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of applications submitted in
response to Fiscal Year 2009 Requests for
Applications related to the following
individual research announcement: CE09–
009, Youth Violence Prevention through
Economic, Environmental, and Policy
Change (U01).
Agenda items are subject to change as
priorities dictate.
Due to programmatic issues that had to be
resolved, the Federal Register notice is being
published less than fifteen days before the
date of the meeting.
Contact Person for More Information: Lisa
T. Garbarino, B.S., NCIPC, Extramural
Research Program Office, CDC, 4770 Buford
Highway, NE., M/S F62, Atlanta, Georgia
30341–3724, Telephone: (404) 723–1527.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: April 21, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–9503 Filed 4–24–09; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
pwalker on PROD1PC71 with NOTICES
(Pub. L. 92–463), CDC announces the
following meeting of the
aforementioned review group:
BILLING CODE 4163–18–P
National Center for Injury Prevention
and Control, Initial Review Group,
(NCIPC, IRG)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
VerDate Nov<24>2008
15:55 Apr 24, 2009
Jkt 217001
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
19097
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0664]
Computational Modeling for
Cardiovascular Devices; Public
Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug Administration
(FDA) is announcing a public workshop
entitled ‘‘Computational Modeling for
Cardiovascular Devices.’’ FDA is cosponsoring the conference with the
National Heart, Blood and Lung
Institute of the National Institutes of
Health and the National Science
Foundation. The purpose of the public
workshop is to facilitate discussion
among FDA and other interested parties
on the use of computational modeling in
the design, development, and evaluation
of cardiovascular medical devices.
Date and Time: The public workshop
will be held on June 1 and 2, 2009, from
8 a.m. to 5 p.m.
Location: The public workshop will
be held at the Hilton Washington DC/
Rockville Executive Meeting Center,
1750 Rockville Pike, Rockville, MD
20852.
Contact Person: Donna R. Lochner,
Center for Devices and Radiological
Health (HFZ–450), Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 240–276–4043, email: donna.lochner@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Why Are We Holding This Public
Workshop?
The purpose of the public workshop
is to facilitate discussion among FDA
and other interested parties on the use
of computational modeling in
cardiovascular device design,
development, and evaluation.
II. What Are the Topics We Intend to
Address at the Public Workshop?
We hope to discuss a large number of
issues at the public workshop,
including, but not limited to:
• Multi-scale modeling.
• Imaging for cardiovascular device
modeling.
• Physiologic input data for
cardiovascular device modeling.
• Device-specific issues related to
modeling, including a focus on heart
valves, drug-eluting and bare metal
stents, endovascular stents, cardiac
rhythm management, and mechanical
and circulatory support devices.
E:\FR\FM\27APN1.SGM
27APN1
Agencies
[Federal Register Volume 74, Number 79 (Monday, April 27, 2009)]
[Notices]
[Pages 19096-19097]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-9521]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2007-D-0430] (formerly Docket No. 2007D-0166)
International Cooperation on Harmonisation of Technical
Requirements for Registration of Veterinary Medicinal Products (VICH);
Guidance for Industry on ``Target Animal Safety for Veterinary
Pharmaceutical Products,'' VICH GL43; Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of a guidance for industry (185) entitled
``Target Animal Safety for Veterinary Pharmaceutical Products,'' VICH
GL43. The purpose of this harmonized guidance is to provide
recommendations regarding target animal safety (TAS) evaluation for
regulatory submission of an Investigational Veterinary Pharmaceutical
Product (IVPP), which is appropriate for determining the safety of an
IVPP in the target animal. The guidance includes recommendations on
including identification of target organs, where possible, and
confirmation of margin of safety, using the minimum number of animals
appropriate for the studies.
DATES: Submit written or electronic comments on agency guidances at any
time.
ADDRESSES: Submit written requests for single copies of the guidance to
the Communications Staff (HFV-12), Center for Veterinary Medicine, Food
and Drug Administration, 7519 Standish Pl., Rockville, MD 20855. Send
one self-addressed adhesive label to assist that office in processing
your requests.
Submit written comments on the guidance to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852. Submit electronic comments to https://www.regulations.gov. See the SUPPLEMENTARY INFORMATION section for
electronic access to the guidance document.
FOR FURTHER INFORMATION CONTACT: Steven Vaughn, Center for Veterinary
Medicine, (HFV-100), Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855, 240-276-8300, e-mail: steven.vaughn@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In recent years, many important initiatives have been undertaken by
regulatory authorities and industry associations to promote the
international harmonization of regulatory requirements. FDA has
participated in efforts to enhance harmonization and has expressed its
commitment to seek scientifically based harmonized technical procedures
for the development of pharmaceutical products. One of the goals of
harmonization is to identify and then reduce differences in technical
requirements for drug development among regulatory agencies in
different countries.
FDA has actively participated in the International Conference on
Harmonisation of Technical Requirements for Approval of Pharmaceuticals
for Human Use (VICH) for several years to develop harmonized technical
requirements for the approval of human pharmaceutical and biological
products among the European Union, Japan, and the United States. The
VICH is a parallel initiative for veterinary medicinal products. The
VICH is concerned with developing harmonized technical requirements for
the approval of veterinary medicinal products in the European Union,
Japan, and the United States, and includes input from both regulatory
and industry representatives.
The VICH Steering Committee is composed of member representatives
from the European Commission, European Medicines Evaluation Agency,
European Federation of Animal Health, Committee on Veterinary Medicinal
Products, the U.S. FDA, the U.S. Department of Agriculture, the Animal
Health Institute, the Japanese Veterinary Pharmaceutical Association,
the Japanese Association of Veterinary Biologics, and the Japanese
Ministry of Agriculture, Forestry and Fisheries.
Four observers are eligible to participate in the VICH Steering
Committee: One representative from the government of Australia/New
Zealand, one representative from the industry in Australia/New Zealand,
one representative from the government of Canada, and one
representative from the industry of Canada. The VICH Secretariat, which
coordinates the preparation of documentation, is provided by the
International Federation for Animal Health (IFAH). An IFAH
representative also participates in the VICH Steering Committee
meetings.
II. Guidance on Target Animal Safety for Veterinary Pharmaceutical
Products
In the Federal Register of May 18, 2007 (72 FR 28058), FDA
published the notice of availability for a draft guidance entitled
``Draft Guidance for Industry on Target Animal Safety for Veterinary
Pharmaceutical Products,'' which gave interested persons until June 18,
2007, to comment on the draft guidance. FDA received a few comments on
the draft guidance and those comments as well as those received by
other VICH member regulatory agencies were considered as the guidance
was finalized. Based on the comments received, the VICH Expert Working
Group on Target Animal Safety clarified the guidance's recommendations
regarding the development and conduct of TAS studies. In particular,
the Expert Working Group revised the sections addressing necropsy and
histopathology examinations and mammary gland studies to clarify the
recommendations regarding these topics. At a meeting held in July 2008,
the VICH Steering Committee endorsed the final guidance for industry,
(VICH GL43). The guidance announced in this notice finalizes the draft
guidance dated May 18, 2007.
This guidance document is intended to cover TAS evaluation for any
IVPP used in the following species: Bovine, ovine, caprine, feline,
canine, porcine, equine, and poultry (chickens and turkeys). The
recommendations in this guidance may not be appropriate for
registration by national or regional authorities of products for use in
minor species or minor uses. The guidance does not provide information
for the design of TAS studies in other species, including aquatic
animals. For other species and for minor uses, TAS studies should be
designed following national or regional guidance.
III. Significance of Guidance
This guidance document, developed under the VICH process, has been
revised to conform to FDA's good guidance practices regulation (21 CFR
10.115). For example, the document has been designated ``guidance''
rather than
[[Page 19097]]
``guideline.'' In addition, guidance documents must not include
mandatory language such as ``shall,'' ``must,'' ``require,'' or
``requirement,'' unless FDA is using these words to describe a
statutory or regulatory requirement. The guidance represents agency's
current thinking on the topic. It does not create or confer any rights
for or on any person and does not operate to bind FDA or the public. An
alternative approach may be used if such approach satisfies the
requirements of applicable statutes and regulations.
IV. Paperwork Reduction Act of 1995
This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The
collections of information in sections 1-5 of the guidance have been
approved under OMB control no. 0910-0032 (expiration date April 30,
2010).
V. Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. Received comments may be seen in the
Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
VI. Electronic Access
Persons with access to the Internet may obtain the guidance at
either https://www.fda.gov/cvm or https://www.regulations.gov.
Dated: April 20, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-9521 Filed 4-24-09; 8:45 am]
BILLING CODE 4160-01-S